Component information
No US or EU label exists for this exact combination, so information is shown for each component.
Use: ATROPEN is indicated for the treatment of poisoning by susceptible organophosphorus nerve agents having cholinesterase activity as well as organophosphorus or carbamate insecticides in adult and pediatric patients. US FDA label
- Hyoscine-n-butylbromide listed as hyoscine
Use: Gastrointestinal and genitourinary spasm (tablets) renalcarematters.com, reviewed
Kidney dosing: Hyoscine-n-butylbromide (single-agent)Show full dosing details
- CrCl ≥60 mL/min
- Tablets: 10 to 20 mg per dose, maximum 60 mg/day. Injection: 10 to 20 mg slowly IV, IM or SC, maximum 100 mg/day (PM).
- CrCl 30–59 mL/min
- The prescribing information gives no kidney dosing. Tablets: negligible absorption, kidney accumulation unlikely. Injection: about half of an intravenous dose is excreted unchanged in urine; use the lowest dose and watch for anticholinergic effects.
- CrCl 15–29 mL/min
- The prescribing information gives no kidney dosing. Tablets: negligible absorption, kidney accumulation unlikely. Injection: about half of an intravenous dose is excreted unchanged in urine; use the lowest dose and watch for anticholinergic effects.
- CrCl <15 mL/min (not on dialysis)
- The prescribing information gives no kidney dosing. Tablets: negligible absorption, kidney accumulation unlikely. Injection: about half of an intravenous dose is excreted unchanged in urine; use the lowest dose and watch for anticholinergic effects.
- Hemodialysis (intermittent)
- Not studied in dialysis; no dose given.
- Peritoneal dialysis
- Not studied in dialysis; no dose given.
- CRRT
- Not studied in dialysis; no dose given.
- Dialyzable? Not stated.
- Monitoring Anticholinergic effects: urinary retention, tachycardia, hypotension after injection (observe; emergency equipment available), raised intraocular pressure (urgent review for painful red eye). Avoid IM injection in anticoagulated patients (PM).
From the Hyoscine-n-butylbromide monograph (renalcarematters.com, reviewed).
- hyoscyamine no separate page
Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney dosing for each component (single-agent) is shown under Component information.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- Tablet: 103.7 mcg/19.4 mcg/6.5 mcg
Registered products in the Philippines
1 product registered with the Food and Drug Administration (FDA) Philippines list Atropine + Hyoscine + Hyoscyamine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
DonnatabHyoscyamine Sulfate + Atropine Sulfate + Hyoscine Hydrobromide | 103.7 mcg/19.4 mcg/6.5 mcg TabletBlister Pack x 25's (Box of 25's and 50's) | Rx | Interphil Laboratories, Inc.Philippines | — | DR-XY31283 (FOR EXPORT ONLY) | Nov 24, 2030 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .